FluMist warning letter
This article was originally published in Pharmaceutical Approvals Monthly
Manufacturing deficiencies at MedImmune's Liverpool, U.K. manufacturing facility for the live intranasal flu vaccine FluMist are not expected to affect the availability of the influenza vaccine for the 2007-2008 flu season, according to FDA. The agency issued a warning letter to MedImmune May 24, citing the company for several significant deviations from current good manufacturing practice in the manufacture of FluMist bulk monovalent lots stemming from an inspection between March 21 and March 27. MedImmune said it expects to have 7 million doses of FluMist available for the 2007-2008 influenza season. The deficiencies will delay approval of MedImmune's sBLA for FluMist seeking to extend the age indication for the vaccine. FDA issued a "complete response" letter for the sBLA May 25, pending resolution of the outstanding issues...
You may also be interested in...
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. And London-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.